ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,717.90
-0.08%
S&P ASX All Technology
3,083.40
-0.30%
Brent Oil
82.135
0.01%
US Dollar vs AUD
1.51439
0.04%
Bitcoin
66,307.20
-0.50%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Veru Inc (VERU)

  7. Veru Inc (VERU) News

VERU Veru Inc

0.825
-0.0135 (-1.61%)
15 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Veru Inc VERU NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
-0.0135 -1.61% 0.825 14:00:07
Open Price Low Price High Price Close Price Previous Close
0.8382 0.7953 0.8468 0.8133 0.8385
more quote information »

Recent News

Date Time Source Heading
10/6/202422:30GLOBEVeru to Present at the American Diabetes Association's 84th..
29/5/202407:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/5/202408:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/5/202408:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/5/202406:10EDGAR2Form 8-K - Current report
22/5/202422:30GLOBEVeru to Present at the Jefferies Global Healthcare..
18/5/202409:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/5/202409:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/5/202422:30GLOBEVeru Announces Steven B. Heymsfield M.D. as the Principal..
14/5/202422:30GLOBEVeru Announces Mitchell Steiner as Keynote Speaker at Biomed..
10/5/202406:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/5/202406:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/5/202405:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/5/202405:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/5/202403:06EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
10/5/202403:02EDGAR2Form DEFR14A - Revised definitive proxy soliciting materials
09/5/202403:09EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/5/202421:00EDGAR2Form 8-K - Current report
08/5/202420:30GLOBEVeru Reports Fiscal 2024 Second Quarter Financial Results..
02/5/202422:30GLOBEVeru to Present at the GLP-1 Based Therapeutics Summit
01/5/202422:30GLOBEVeru to Report Fiscal 2024 Second Quarter Financial Results..
30/4/202422:30GLOBEVeru Enrolls First Patients in Phase 2b Clinical Trial of..
25/4/202422:30GLOBEVeru to Present at the American Association of Clinical..
02/4/202407:05GLOBEVeru Announces Date of 2024 Annual Meeting of Shareholders
23/3/202407:05GLOBEVeru Reschedules Annual Meeting of Shareholders
12/3/202423:00GLOBEVeru Announces the Appointment of Louis Aronne MD as Chief..
28/2/202411:15GLOBEVeru Announces Notification from Nasdaq Related to Delayed..
21/2/202400:30GLOBEVeru Announces New Scientific Advisory Board for its..
16/2/202408:49EDGAR2Form NT 10-Q - Notification of inability to timely file Form..
16/2/202408:06EDGAR2Form 8-K - Current report
15/2/202408:32EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08/2/202423:00EDGAR2Form 8-K - Current report
08/2/202422:30GLOBEVeru Reports Fiscal 2024 First Quarter Financial Highlights
07/2/202408:27EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
07/2/202400:30GLOBEVeru Announces FDA Clearance of IND Application to Initiate..
01/2/202400:30GLOBEVeru to Present at the Oppenheimer 34th Annual Healthcare..
27/1/202408:06EDGAR2Form 8-K - Current report
27/1/202401:02EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
27/1/202401:00EDGAR2Form DEF 14A - Other definitive proxy statements
26/1/202400:30GLOBEVeru to Report Fiscal 2024 First Quarter Financial Results..
09/1/202400:30GLOBEVeru Submits IND Application to FDA for the Development of..
27/12/202308:31EDGAR2Form SC 13G - Statement of acquisition of beneficial..
20/12/202300:30GLOBEVeru to Host Investor Call on January 4th, 2024 to Discuss..
19/12/202301:01EDGAR2Form 8-K - Current report
16/12/202308:04EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
15/12/202301:00GLOBEVeru Announces Pricing of Public Offering of Common Stock
14/12/202308:23EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
14/12/202308:06EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
14/12/202308:04EDGAR2Form 8-K - Current report
14/12/202308:01GLOBEVeru Announces Proposed Public Offering of Common Stock

Your Recent History

NASDAQ
VERU
Veru
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved